Current Duke Appointments & Affiliations
Adjunct Professor in the Department of Medicine
·
2026 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2008 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.
Journal article Nat Med · September 29, 2026 Werner syndrome helicase (WRN) is a synthetic lethal target for microsatellite instability (MSI) cancers. In part 1 of this ongoing first-in-human, phase 1 trial, escalating doses of RO7589831 (VVD-133214), a first-in-class, WRN covalent inhibitor, were ev ... Full text Link to item CiteZolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial.
Journal article ESMO Gastrointest Oncol · September 2026 There remains an unmet need for additional treatment options for patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced (LA) unresectable, or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma whose tu ... Full text Link to item CiteSafety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.
Journal article ESMO Open · September 2026 BACKGROUND: In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRASG12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). CodeBreaK ... Full text Link to item CiteRecent Grants
The Duke University - Duke Cancer Institute National Clinical Trials Network Lead Academic Participating Site (UG1) Support Grant
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2019 - 2032Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Revolution Medicines, Inc · 2026 - 2031A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
Clinical TrialPrincipal Investigator · Awarded by Servier Bio-Innovation, LLC · 2026 - 2031View All Grants
Education
The University of Chicago ·
2005
M.D.